Mestag Therapeutics Alternatives & Competitors
12 companies similar to Mestag Therapeutics — New therapies for inflammatory disease and cancer by targeting fibroblast immuno...
Companies similar to Mestag Therapeutics
-Ltd.-logo. "CV6 Therapeutics, (NI) Ltd."){kind=logo}
CV6 Therapeutics, (NI) Ltd.
CV6 Therapeutics is dedicated to improving patients lives through the development of novel...
United Kingdom
Macomics
Macrophage Biology Revealed:Developing breakthrough approaches to macrophage activity to c...
Edinburgh, United Kingdom
ROME Therapeutics
Harnessing the power of the repeatome to develop a new class of therapies for cancer and a...
Boston, United States
3T Biosciences
3T is an immunotherapy company developing next-generation, transformative therapies for br...
South San Francisco, Unit...
Rival Readout
Competing with Mestag Therapeutics? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Sitryx
Harnessing the power of cell metabolism to develop groundbreaking disease-modifying therap...
Oxford, United Kingdom
Invivyd
Vaccines can only take us so far. Antibodies are the natural next step.
New Haven, United States
Arcus Biosciences
Biopharmaceutical company developing differentiated molecules and combination therapies fo...
Hayward, United States
Antharis Therapeutics, Inc.
Antharis Therapeutics is a multinational biopharmaceutical company developing new, cutting...
San Diego, United States
Mersana Therapeutics
Our mission is to discover and develop life-changing antibody-drug conjugates (ADCs) for p...
Cambridge, United States
NBE-Therapeutics AG
Next generation antibody drug conjugates
Basel, Switzerland
Repertoire Immune Medicines
Repertoire is a biotechnology company creating a new category of immune medicines for canc...
Cambridge, United States
About Mestag Therapeutics
Mestag Therapeutics, founded in 2020 and headquartered in the United Kingdom, is at the forefront of developing innovative treatments for inflammatory diseases and cancer. Utilizing its expertise in fibroblast immunology, Mestag is advancing a strategic pipeline of first-in-class antibody programs that promise signific...
Development of first-in-class antibodies, Therapeutics targeting fibroblast immunology, Advanced research in cancer and inflammatory diseases, Agonist antibodies for immune response regulation
Patients with cancer, Patients with inflammatory diseases such as RA, IBD, and lupus, Healthcare providers, Research organizations in immunology
Fibroblast Technology, Immunology, Oncology, Inflammatory Disease, Antibody Programs, Immune Interactions, Cancer Treatment, Immuno-oncology, Therapeutics, Drug Development, Innovative Treatments, Fibroblast-immune Interactions, First-in-class Therapies, Biopharmaceuticals
B2B, B2D
Licensing, Performance Based
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Mestag Therapeutics: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Mestag Therapeutics on 18 Mar 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 22 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
